The final analysis of the two-year PEARL study, presented at the 2025 European Academy of Neurology Congress, demonstrated the sustained effectiveness of fremanezumab, an anti-CGRP monoclonal antibody, in preventing migraine attacks. The study, which included over 1,100 patients with chronic and episodic migraine, revealed high injection adherence rates and consistent safety and tolerability. The primary endpoint of a 50% or greater reduction in monthly migraine days was achieved by a significant portion of patients, and these benefits were maintained throughout the two-year period.
These findings are particularly important given the substantial impact of migraine on individual well-being and societal productivity. The high adherence rate suggests that fremanezumab offers a practical and manageable treatment option for patients seeking long-term migraine prevention. Demonstrating sustained effectiveness over two years provides further confidence in the drug’s ability to provide consistent relief, potentially reducing the need for patients to switch therapies or experience breakthrough migraine attacks. This contributes to improved patient outcomes and reduces the overall burden of migraine.
The study demonstrated a sustained effectiveness for over two years in roughly 66% of patients with episodic migraine and 52% with chronic migraine, who initially achieved a 50% reduction in monthly migraine days. Injection adherence remained consistently high at approximately 90%, with over 75% of participants completing the full study duration. The safety profile remained consistent with previous trials.
This comprehensive, real-world data strengthens the position of fremanezumab as a viable long-term treatment option for migraine prevention. The positive results, coupled with the high adherence rates, suggest continued growth in the adoption of fremanezumab, benefiting both patients and Teva. Further research could explore the impact of this preventive treatment on quality of life measures, healthcare resource utilization, and overall economic burden of migraine.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
